Janus Henderson Group Portfolio holdings
Janus Henderson Group, formed in 2017 through the merger of Janus Capital Group (founded 1969) and Henderson Group (founded 1934), is a global asset management firm headquartered in London, managing over $350 billion in assets as of late 2024 for institutional, retail, and high-net-worth clients. With a strong presence in the U.S., Europe, and Asia-Pacific, the firm offers a wide range of investment products, including equities, fixed income, multi-asset, and alternative strategies, often blending active management with research-driven insights. Known for its equity expertise from Janus’s growth-focused heritage and Henderson’s European fixed-income strengths, Janus Henderson serves clients through mutual funds, ETFs, and bespoke portfolios, emphasizing risk-adjusted returns and ESG integration. Led by CEO Ali Dibadj since 2022, the publicly traded firm (NYSE: JHG) continues to refine its strategy amid competitive pressures, maintaining a foothold in key markets worldwide.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$566M |
| 2 |
Meta Platforms (Facebook)
META
|
+$401M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
+$366M |
| 4 |
Align Technology
ALGN
|
+$356M |
| 5 |
PayPal
PYPL
|
+$278M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$564M |
| 2 |
Alibaba
BABA
|
+$511M |
| 3 |
Altria Group
MO
|
+$439M |
| 4 |
Revvity
RVTY
|
+$321M |
| 5 |
Merck
MRK
|
+$316M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 30.77% |
| 2 | Healthcare | 19.73% |
| 3 | Consumer Discretionary | 11.5% |
| 4 | Financials | 9.61% |
| 5 | Communication Services | 8.19% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
FOLD
201
DELISTED
Amicus Therapeutics
FOLD
| $199M | 0.1% |
14,106,259
+2,312,500
| +20% | +$33.7M |
|
202
Royalty Pharma
RPRX
$26.6B
| $199M | 0.1% |
4,724,644
+217,506
| +5% | +$9.33M |
|
|
GWPH
203
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
| $199M | 0.1% |
2,041,289
+319,972
| +19% | +$36.8M |
|
204
Insmed
INSM
$22.6B
| $198M | 0.1% |
6,169,167
-3,073,205
| -33% | -$88.3M |
|
205
Union Pacific
UNP
$175B
| $197M | 0.1% |
1,000,392
+206,001
| +26% | +$38.3M |
|
|
RP
206
DELISTED
RealPage, Inc.
RP
| $196M | 0.1% |
3,395,193
-547,783
| -14% | -$33.9M |
|
207
Illumina
ILMN
$29.2B
| $196M | 0.1% |
650,548
+349,485
| +116% | +$120M |
|
208
Caesars Entertainment
CZR
$6.1B
| $195M | 0.1% |
3,475,888
+2,867,568
| +471% | +$126M |
|
209
Elevance Health
ELV
$83.7B
| $192M | 0.1% |
714,583
-74,263
| -9% | -$20M |
|
210
Integra LifeSciences
IART
$1.54B
| $191M | 0.1% |
4,049,872
-145,314
| -3% | -$6.91M |
|
211
Regeneron Pharmaceuticals
REGN
$72.9B
| $191M | 0.1% |
341,587
+46,572
| +16% | +$28.2M |
|
212
CVS Health
CVS
$140B
| $191M | 0.1% |
3,272,041
+1,256,506
| +62% | +$78.2M |
|
213
Kraft Heinz
KHC
$32.4B
| $189M | 0.1% |
6,301,899
+2,172,899
| +53% | +$72.3M |
|
214
Clorox
CLX
$12.1B
| $188M | 0.1% |
893,649
+29,318
| +3% | +$6.53M |
|
215
Visteon
VC
$2.85B
| $186M | 0.1% |
2,683,100
-8,199
| -0.3% | -$606K |
|
216
Pfizer
PFE
$144B
| $186M | 0.1% |
5,329,128
-489,319
| -8% | -$17.2M |
|
217
Berkshire Hathaway Class B
BRK.B
$1.11T
| $185M | 0.1% |
868,641
-40,466
| -4% | -$8.28M |
|
218
West Pharmaceutical
WST
$23.7B
| $185M | 0.1% |
671,942
+43,155
| +7% | +$11.4M |
|
219
Bio-Techne
TECH
$11.2B
| $184M | 0.1% |
2,963,284
-406,064
| -12% | -$26.4M |
|
220
Parker-Hannifin
PH
$125B
| $180M | 0.09% |
890,403
-28,571
| -3% | -$5.62M |
|
221
MSCI
MSCI
$42.1B
| $180M | 0.09% |
503,248
-6,201
| -1% | -$2.25M |
|
222
ServiceNow
NOW
$114B
| $179M | 0.09% |
1,840,935
-203,075
| -10% | -$18.1M |
|
|
ALXN
223
DELISTED
Alexion Pharmaceuticals
ALXN
| $177M | 0.09% |
1,547,353
+1,313,698
| +562% | +$142M |
|
224
Blackbaud
BLKB
$1.65B
| $176M | 0.09% |
3,145,087
-12,861
| -0.4% | -$771K |
|
|
GRMN
225
Garmin
GRMN
$48.9B
| $174M | 0.09% |
1,839,528
+112,201
| +6% | +$11.2M |
|
Similar funds
Janus Henderson Group's Q3 2020 Portfolio in Review
As of Q3 2020, Janus Henderson Group held 1,403 positions worth $192B, up 7.7% from $178B the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Janus Henderson Group's Q3 2020 filing shows 105 new, 521 increased, 678 reduced and 86 closed positions. Its largest new stake was Acceleron Pharma: 1,783,939 shares worth $201M. The largest sale was Apple, an estimated $564M.
By sector, the portfolio is most concentrated in Technology at 31% of assets, up from 31% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- Janus Henderson Group's largest Q3 2020 buy was Acceleron Pharma: 1,783,939 shares worth $201M.
- Janus Henderson Group added most to Booking.com in Q3 2020, an estimated $566M increase.
- Janus Henderson Group's biggest Q3 2020 reduction was Apple, cutting an estimated $564M.
- Janus Henderson Group fully exited Momenta Pharmaceuticals, Inc. in Q3 2020, selling an estimated $49.5M.
- Janus Henderson Group's ten largest holdings make up 24% of its $192B portfolio in Q3 2020.
- Janus Henderson Group opened 105 new positions and closed 86 in Q3 2020.
- Janus Henderson Group's portfolio value rose 7.7% quarter-over-quarter to $192B.
Based on Janus Henderson Group's 13F filing for Q3 2020, filed 16 Nov 2020.